DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $14.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target increased by equities research analysts at Robert W. Baird from $12.00 to $14.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. Robert W. Baird’s price objective suggests a potential upside of 10.15% from the stock’s current price.

XRAY has been the topic of several other reports. Barrington Research reaffirmed an “outperform” rating and issued a $14.00 target price on shares of DENTSPLY SIRONA in a research report on Monday, January 5th. UBS Group dropped their price objective on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Zacks Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Wells Fargo & Company decreased their target price on shares of DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Finally, Stifel Nicolaus set a $13.00 price target on DENTSPLY SIRONA in a report on Thursday, November 6th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus price target of $14.62.

DENTSPLY SIRONA Price Performance

XRAY opened at $12.71 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. The company’s 50-day moving average price is $12.35 and its 200 day moving average price is $12.47. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $19.03. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -2.88, a price-to-earnings-growth ratio of 1.01 and a beta of 1.01.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Transactions at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Eurizon Capital SGR S.p.A. bought a new stake in shares of DENTSPLY SIRONA in the 4th quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA in the first quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its holdings in shares of DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares in the last quarter. Huntington National Bank lifted its position in shares of DENTSPLY SIRONA by 292.9% during the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 2,077 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Q4 sales topped expectations — reported net sales of $961M (up 6.2% year-over-year), which beat consensus and supports demand resilience in the core dental business. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management announced a Return-to-Growth plan redirecting ~ $120M annually toward innovation, clinical education and sales — a signal of reinvestment to drive longer-term growth. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Capital-allocation shift: dividend eliminated to prioritize debt reduction and share repurchases — could improve leverage and support EPS over time. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Commercial and product progress: new distribution agreements (Patterson, Benco, Burkhart, A-dec) and a U.S. product launch (Surity™ catheter) expand addressable markets and distribution reach. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Adjusted results: adjusted EPS was $0.27 (company figure), roughly flat year-over-year — shows operational stability but not a clear beat. MarketBeat Earnings Summary
• Negative Sentiment: GAAP loss and one-time charges: Q4 reported net loss of $146M driven by $144M of goodwill and intangible impairments, which produced a material headline loss. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Small EPS miss: reported adjusted EPS of $0.27 missed the consensus by $0.01 — a modest disappointment that can pressure near-term sentiment. Zacks: Q4 Earnings Miss
• Negative Sentiment: FY-2026 guidance below revenue expectations: management guided to $3.5B–$3.6B revenue (below Street ~ $3.7B) and EPS $1.40–$1.50 — revenue shortfall is a near-term headwind for the stock. Guidance in Press Release
• Negative Sentiment: Shareholder litigation inquiry: Halper Sadeh LLC is investigating potential board/officer fiduciary breaches, which can create governance/legal overhang. PR Newswire: Halper Sadeh Inquiry

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.